Liver function test elevations occur rarely in patients with psoriasis and hidradenitis suppurativa (HS) treated with biologics, according to a Dermatology Times report summarizing clinical experience with the drug class across both inflammatory skin diseases.

The finding matters for two cohorts dermatologists manage daily. Psoriasis patients frequently carry metabolic comorbidities — nonalcoholic fatty liver disease, obesity, alcohol use — that already raise transaminases before any immunomodulator enters the picture. HS patients, similarly, show elevated rates of metabolic syndrome. Against that background, a signal that biologics themselves seldom drive hepatotoxicity is clinically useful at the point of prescribing.

Why the hepatic question persists

The concern is inherited largely from the psoriasis treatment era that preceded biologics. Methotrexate, still widely used, carries a well-characterized risk of hepatotoxicity and requires protocol-driven liver surveillance, which in many patients means serial monitoring or even biopsy decisions over years of therapy. Retinoids and, historically, other systemic agents added to the impression that systemic psoriasis treatment and liver risk travel together.

Biologics entered practice with a different safety question set — serious infection, malignancy, immunogenicity — yet liver monitoring remained embedded in many clinicians' routines and in package-insert language for several agents. The new reporting aligns with the accumulating real-world view that clinically meaningful transaminase elevations attributable to biologic therapy are the exception, not the rule, in psoriasis and HS.

What this means in the clinic

For prescribers, the practical takeaway is a recalibration of monitoring intensity rather than its abandonment:

• Baseline liver function testing remains reasonable, given how often comorbid liver disease surfaces in psoriasis and HS populations at first assessment.
• Routine, frequent repeat LFTs purely because a biologic is on board draw decreasing support, and add cost and patient burden.
• When transaminases do rise on biologic therapy, the workup should look first at the usual suspects — fatty liver disease, alcohol, concomitant hepatotoxic medications, viral hepatitis — before attributing causality to the biologic.
• Alternative causes deserve particular attention in HS, where long antibiotic courses and analgesic exposure can confound the picture.

That causality discipline matters. A spurious attribution of LFT elevation to a biologic can push a clinician to interrupt or abandon an agent that was controlling disease, exposing the patient to flare risk and the loss of a hard-won treatment response in conditions where effective options remain finite.

Context for both indications

The pairing of psoriasis and HS in the reporting is notable because the two diseases sit at different points in the biologic evidence lifecycle. Psoriasis biologics — TNF, IL-17, IL-23 and IL-12/23 inhibitors — carry the deepest long-term safety databases in dermatology, with registry-scale follow-up. HS biologics, principally anti-TNF therapy and, more recently, IL-17 inhibition, rest on a younger and smaller evidence base, so post-marketing and real-world safety signals such as this one carry proportionally more weight for HS prescribing decisions.

For both populations, hepatic safety reassurance supports treatment persistence, which in turn supports the outcomes dermatologists actually measure — PASI response in psoriasis maintained over years, and pain and flare reduction in HS sustained beyond induction.

The road ahead

As biologic use in HS expands and longer-duration psoriasis registries mature, expect hepatic safety data to grow more granular by agent and by class, giving clinicians firmer grounds to tailor — and likely simplify — liver monitoring for patients on long-term biologic therapy.